Share purchase agreement dated December 24, 2020 entered into amongst Lavender Rose Investment Ltd, Gangadi
Madhukar Reddy, Gangadi Investments Private Limited, Agilemed Investments Private Limited, Lone Furrow Investments
Private Limited and our Company

Pursuant to the share purchase agreement dated December 24, 2020, Lavender Rose Investment Ltd purchased 108,221 equity
shares of our Company, constituting 20.51% of the then share capital on a fully diluted basis as on the closing date, from
Gangadi Investments Private Limited for a consideration of % 5.21 billion.

Key terms of share subscription agreements

Share subscription agreement dated February 22, 2019 entered into amongst PI Opportunities Fund — I, Gangadi Madhukar
Reddy, Gangadi Investments Private Limited and our Company

Pursuant to the share subscription agreement dated February 22, 2019, PI Opportunities Fund - I subscribed to 100 equity shares
and 30,747 Series A CCPS of our Company for a consideration of 2 2.04 billion.

Share subscription agreement dated December 24, 2020 entered into amongst Lavender Rose Investment Ltd, Agilemed
Investments Private Limited, Lone Furrow Investments Private Limited, Gangadi Madhukar Reddy, Gangadi Investments
Private Limited and our Company

Pursuant to the share subscription agreement dated December 24, 2020, Lavender Rose Investment Ltd subscribed to 560,896
Series C1 CCPS of our Company for a consideration of % 777.90 million.

Share subscription agreement dated December 24, 2020 entered into amongst PI Opportunities Fund - I, Agilemed
Investments Private Limited, Lone Furrow Investments Private Limited, Gangadi Madhukar Reddy, Gangadi Investments
Private Limited and our Company

Pursuant to the share subscription agreement dated December 24, 2020, PI Opportunities Fund - I exercised its pre-emptive
rights as per the shareholders’ agreement dated February 22, 2019 and subscribed to 160,147 Series C2 CCPS of our Company
for a consideration of % 222.10 million.

Other Key Agreements

Inter investor agreement dated January 27, 2021 entered into between Morning Brook Investment Ltd, Zash Traders
(together “Debenture Holders”), Vistra ITCL (India) Limited, PI Opportunities Fund — I, Lavender Rose Investment Ltd,
Gangadi Madhukar Reddy, Gangadi Investments Private Limited, Agilemed Investments Private Limited, Lone Furrow
Investments Private Limited and the Company (together, the “Parties”) (“Inter-Investor Agreement”) as amended by the
waiver cum amendment agreement to the Inter-Investor Agreement, dated August 5, 2021 (“Inter-Investor WCA”)

Pursuant to the share subscription agreements and the SHA, the Inter-Investor Agreement was entered into in order for the
Debenture Holders to provide consent for the issuance of bonus and subscription shares by our Company, conversion of any
convertible shares issued to PI Opportunities Fund — I and Lavender Rose Investment Ltd and amendment of charter documents
of our Company, Agilemed and Lone Furrow to incorporate terms of the SHA. Further, the Inter-Investor Agreement states the
rights, powers and remedies available to the parties to the agreement in case of an event of default.

Pursuant to the Inter-Investor WCA, PIOF and Lavender Rose have, inter alia, waived their right to first offer and tag along
with respect to the encumbered shares held by the Promoters, pledged as security under the debenture documents with effect
from August 5, 2021.

The Inter-Investor WCA shall stand terminated if (i) the initial public offering of the Equity Shares on the Stock Exchanges is
not completed on or prior to the six months from the filing of the draft red herring prospectus or any such other timeline as may
be mutually agreed amongst the Promoters, PIOF and Lavender Rose or (ii) if the Company and majority of the Selling
Shareholders jointly decide not to undertake the initial public offering. Further, the Inter-Investor WCA shall stand
automatically terminated, in its entirety, upon the listing and trading of Equity Shares of the Company pursuant to an IPO,
without any further act or deed required on the part of any party.

User agreement dated March 1, 2019 entered into between Optival and our Company (“User Agreement”)
Under the User Agreement, our Company has granted Optival a sub-licensable, non-exclusive right to use the trademark
“MEDPLUS” (“Trademark”) in India and abroad, which is a registered trademark under class 42, for services related to

medicinal, pharmaceutical, diagnostic and treatment services, through a number of owned and franchised stores, within India
and operating pharmacy stores across India (“Business”).

182
